*Antibody Technology Interest Network Presentation:*
*Rapid Discovery of Functional Antibodies for SARS-CoV-2*
The COVID-19 pandemic highlights the importance of a flexible and rapid
response to real-time development of medical countermeasures for
life-threatening viral pathogens. Using human B cells from survivors are a
potential source of therapeutic antibodies, Dr. Carnahan will describe the
pandemic response platform developed and deployed at the Vanderbilt Vaccine
Center that has led to a large panel of anti-viral antibodies directed at
SARS-CoV-2, including several antibodies currently in advanced clinical
development.
Rest of post
*Monday, October 26, 2020 11:00 a.m.–12:00 p.m. ET *Register here
<https://us02web.zoom.us/meeting/register/tZEscOiorTsvHNwYx2ZgZi_I9SH5l_OAD8Fj>
Register today to join us for this timely and informative presentation.
Speakers:
*Robert Carnahan, Ph.D.*
<https://www.vumc.org/crowe-lab/person/robert-carnahan-phd>
Associate Director, Vanderbilt Vaccine Center
Associate Professor, Pediatrics and Radiology and Radiologic Sciences
Vanderbilt University Medical Center
*David Blum, Ph.D.* <https://www.bmb.uga.edu/directory/people/david-blum>
Director, Bioexpression and Fermentation Facility
Director, Master of Biomanufacturing and Bioprocessing
University of Georgia